Gainers

• TuHURA Biosciences (NASDAQ:HURA) shares moved upwards by 28.6% to $0.81 during Monday's regular session. The market value of their outstanding shares is at $35.5 million.
• Humacyte (NASDAQ:HUMA) shares rose 27.89% to $1.2. The market value of their outstanding shares is at $175.7 million.
• Tenon Medical (NASDAQ:TNON) stock moved upwards by 24.25% to $0.83. The company's market cap stands at $7.4 million.
• Liminatus Pharma (NASDAQ:LIMN) shares moved upwards by 20.92% to $2.23. The company's market cap stands at $49.7 million.
• Lunai Bioworks (NASDAQ:LNAI) shares increased by 17.13% to $0.78. The company's market cap stands at $15.5 million.
• Entera Bio (NASDAQ:ENTX) shares increased by 16.34% to $1.21. The market value of their outstanding shares is at $47.6 million.

Losers

• Hims & Hers Health (NYSE:HIMS) stock decreased by 23.6% to $17.58 during Monday's regular session. The market value of their outstanding shares is at $5.2 billion.
• Ernexa Therapeutics (NASDAQ:ERNA) stock fell 19.72% to $0.3. The market value of their outstanding shares is at $2.9 million.
• CollPlant Biotechnologies (NASDAQ:CLGN) shares fell 18.74% to $0.65. The market value of their outstanding shares is at $10.2 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) shares declined by 16.84% to $2.5. The market value of their outstanding shares is at $2.5 million.
• AIM ImmunoTech (AMEX:AIM) shares decreased by 16.72% to $0.95. The company's market cap stands at $3.7 million.
• VivoSim Labs (NASDAQ:VIVS) shares decreased by 14.92% to $1.94. The market value of their outstanding shares is at $5.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.